T1	Participants 675 778	One hundred and fifty-five patients were randomized, 144 were evaluable for safety and 142 for response
T2	Participants 785 798	treatment arm
T3	Participants 1269 1280	FM patients
T4	Participants 1324 1337	CHVP patients
T5	Participants 1378 1389	CR patients
T6	Participants 1404 1417	Treatment arm
